BioSyent Inc. (CVE:RX - Get Free Report)'s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$11.14 and traded as high as C$11.21. BioSyent shares last traded at C$11.20, with a volume of 880 shares traded.
BioSyent Trading Down 0.9 %
The firm has a market capitalization of C$126.96 million, a price-to-earnings ratio of 18.01 and a beta of 0.93. The business's 50 day moving average price is C$11.12 and its 200-day moving average price is C$11.06. The company has a debt-to-equity ratio of 2.90, a current ratio of 3.92 and a quick ratio of 6.91.
Insider Activity
In other BioSyent news, insider FAX Capital Corp. sold 112,400 shares of the company's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total transaction of C$1,267,557.28. Also, Senior Officer Robert Joseph March sold 4,775 shares of BioSyent stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Insiders sold 117,707 shares of company stock valued at $1,329,581 in the last three months. 33.65% of the stock is currently owned by company insiders.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
See Also
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
